Beyang Therapeutics Secures $30 Million in Series A Funding for AI-Driven Drug Development
Beyang Therapeutics Successfully Closes $30 Million Series A Funding
Beyang Therapeutics Co., Ltd., a pioneering company in AI-driven drug research and development, has announced the successful completion of an oversubscribed Series A financing round, raising nearly $30 million. This significant funding is poised to propel the development of its innovative ExCEED platform and advance its global clinical development pipeline.
Key Investors and Funding Usage
The latest financing round was co-led by Legend Capital and Shanghai Healthcare Capital, with participation from several strategic investors including China Medical System Holdings Limited, Fenglei Capital, and others. Existing stakeholders such as Root Venture Partners and YuanBio Venture Capital have also reaffirmed their support.
The funds are earmarked for the rapid iteration of Beyang's proprietary AI platform, ExCEED, as well as advancing key pipeline candidates through critical clinical stages. Beyang aims to expand its international research and development and business development teams to accelerate the drug discovery process.
Revolutionary ExCEED Platform
Founded in 2021, Beyang Therapeutics strives to create a
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.